Board of Directors
Rachel Haurwitz, Ph.D.
President and Chief Executive Officer
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-based technologies, and has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. Rachel earned an A.B. in Biological Sciences from Harvard College and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Jeffrey Long-McGie, M.B.A.
Jeff is a Managing Director at Ridgeback Capital Investments. Previously, Jeff served as a Portfolio Manager at JLM Healthcare Advisors, Senior Vice President at Ridgeback Capital Management, Analyst at Sigma Capital, Vice President of Business Development at Andrx Corp., and Vice President / Specialty Pharmaceutical Analyst at ThinkEquity Partners. Jeff started his career in the biotechnology industry with research positions at Onyx Pharmaceuticals, and Genencor Int. He earned his B.S. in Microbiology from California State University, Chico, his M.A. in Biology & Biomedical Sciences from Washington University in St. Louis, and his M.B.A. from Saint Louis University.
Santhosh Palani, Ph.D., CFA
Santhosh is a Partner at PFM Health Sciences where he invests in private and public biotechnology companies. Previously, he was a Principal at New Enterprise Associates (NEA) where he invested in the biopharmaceutical sector and served on the boards of companies in the gene editing, cell therapy, and targeted oncology fields. Prior to that, he was a Vice President at Cowen and Company in Equity Research, where he covered SMID cap Biotechnology stocks. He previously served as an Associate Director in oncology clinical development at Pfizer, and as a Scientist in oncology preclinical development at Takeda Pharmaceuticals (Millennium). He earned his Ph.D. in Bioengineering from the University of Pennsylvania and completed his postdoctoral work in Biochemistry and Molecular Biophysics at Columbia University. He is a CFA® Charterholder.
Natalie Sacks, M.D.
Natalie is an oncologist and is the Chief Medical Officer at Harpoon Therapeutics (NASDAQ: HARP). She serves as a director on the board of Zymeworks, Inc. (NYSE:ZYME) and on the board of STipe Therapeutics. Prior to joining Harpoon, Natalie held various development leadership roles at multiple companies including at Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. She has been responsible for all aspects of development including the late-stage development of oncology therapeutics Kyprolis® and Cometriq™. Natalie held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her M.D. from the University of Pennsylvania School of Medicine, her M.S. in Biostatistics from Harvard University School of Public Health, and her B.A. in Mathematics from Bryn Mawr College.